Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Intravesical Nadofaragene Firadenovec Gene Therapy for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: A Single-Arm, Open-Label, Repeat-Dose Clinical TrialLancet Oncol 2020 Nov 27;[EPub Ahead of Print], SA Boorjian, M Alemozaffar, BR Konety, ND Shore, LG Gomella, AM Kamat, TJ Bivalacqua, JS Montgomery, SP Lerner, JE Busby, M Poch, PL Crispen, GD Steinberg, AK Schuckman, TM Downs, RS Svatek, J Mashni, BR Lane, TJ Guzzo, G Bratslavsky, LI Karsh, ME Woods, G Brown, D Canter, A Luchey, Y Lotan, T Krupski, BA Inman, MB Williams, MS Cookson, KA Keegan, GL Andriole, AI Sankin, A Boyd, MA O'Donnell, D Sawutz, R Philipson, R Coll, VM Narayan, FP Treasure, S Yla-Herttuala, NR Parker, CPN Dinney
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.